Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Weaker Vaccine Causing Whooping Cough Surge

April 27, 2015 8:45 am | by Monash University | News | Comments

A Monash University expert has teamed up with the United States Centers for Disease Control and Prevention to pinpoint the reason behind a surge in whooping cough cases over the past 10 years. Read more....


Scientists Pinpoint Brain-Swelling Mechanism

April 27, 2015 8:41 am | by University of British Columbia | News | Comments

Discovery paves way for treatments to prevent brain damage or death following head trauma. Read more...


MedDay Reports Positive Phase 3 Results from MS Drug Study

April 27, 2015 8:37 am | News | Comments

The study demonstrated evidence of the efficacy and safety of MD1003, a highly-concentrated pharmaceutical-grade biotin administered at a dose of 300 mg per day in the treatment of primary and secondary progressive multiple sclerosis, a major area of unmet medical need. Read more....


Bristol-Myers Gets Positive EMA Opinion for Immunotherapy Drug, Opdivo

April 24, 2015 12:36 pm | by Stephanie Guzowski, Editor | Articles | Comments

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Bristol-Myers Squibb’s Opdivo today for the treatment of melanoma. Read more..


FDA Grants Priority Review for AbbVie's Hepatitis C Treatment

April 24, 2015 12:16 pm | News | Comments

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).  Read more...


J&J Hikes Quarterly Dividend by 7 Percent

April 24, 2015 12:06 pm | by Linda A. Johnson, AP Business Writer | News | Comments

Johnson & Johnson on Thursday said it's raising its quarterly dividend by 7 percent, marking its 53rd straight year of dividend increases. Read more...


Fragile X Syndrome: Building a Case for an Alternative Treatment Strategy

April 24, 2015 12:01 pm | by Emory Health Sciences | News | Comments

New research strengthens a potential strategy for treating fragile X syndrome, the most common inherited form of intellectual disability. Read more...


How to Identify Drugs that Work Best for Each Patient

April 24, 2015 11:53 am | by Anne Trafton, MIT News | News | Comments

Implantable device could allow doctors to test cancer drugs in patients before prescribing chemotherapy. Read more...


Hope for an Effective Malaria Therapy with Just One Tablet

April 24, 2015 8:54 am | by Medical University of Vienna | News | Comments

Approximately 584,000 people worldwide die of malaria each year. Read more...


Manchester Joins European Consortium to Develop Liquid Biopsies

April 24, 2015 8:47 am | by University of Manchester | News | Comments

An international project to validate blood-based biomarkers for cancer has added a new member. Read more...


New Gel Medication Delays Release of Drug to Benefit Patients

April 24, 2015 8:38 am | by University of Huddersfield | News | Comments

Gellan gum pharmaceutical development both delays drug release for maximum effect and can be administered as fluid to aid those who have difficulty swallowing pills. Read more....


Protein Links Point to Future Alzheimer's Treatments

April 24, 2015 8:29 am | by University of Cambridge | News | Comments

Researchers have identified how proteins that play a key role in Alzheimer’s disease are linked in a pathway that controls its progression. Read more....


Wellness Advocate, Bestselling Author: I Faked Cancer

April 24, 2015 8:21 am | by Seth Augenstein, Digital Reporter | Articles | Comments

A woman who became a bestselling author and wellness advocate after she claimed she healed herself of a brain tumor through a healthy diet recently admitted she never had cancer. Read more...


FDA Grants Priority Review for Boehringer Ingelheim's Idarucizumab

April 23, 2015 2:06 pm | News | Comments

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for idarucizumab. Read more...


FDA Accepts Filing of Bayer's MS Treatment

April 23, 2015 2:03 pm | News | Comments

Bayer is pleased to announce today that the U.S. Food and Drug Administration (FDA) has accepted the filing for Bayer's supplemental Biologics License Application (sBLA) for Betaconnect (proposed name), another delivery option for Betaseron (interferon beta-1b), a treatment for relapsing-remitting multiple sclerosis. 



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.